A dual role of prestimulus spontaneous neural activity in visual object recognition
... General 10031.0 0.8 0.6 H it ra te 0.4 0.2 0.0 1.0 3 100 80 60 40 20 0 2 1 –1 0 0.8 0.6 F A r at e C rit ... on subjective recognition rate. First, we found that a “yes” report on a previous trial (as compared to a “no ...
NYU Clinical Laboratory Reference Ranges
... MONOXIDE EXPOSURE (GEM) Analyte: CARBOXYHEMOGLOBIN, CO EXPOSURE, POC (-RA (123420110); result units ... ) Unspecified Unspecified Not-Detected POCT Activated Clotting Time (iStat) Analyte: ACT ISTAT-POC (-RALS ...
15320836375239 1..25
... Competing interests: The authors declare that no competing interests exist. Funding: See page 21 Received ... ). Second (bottom-right panel, ‘between- Figure 3 continued on next page González-Garcı́a et al. eLife 2018 ...
15524834454790 1..25
... that no competing interests exist. Funding: See page 21 Received: 09 September 2018 Accepted: 25 February 2019 ... Life.41861 23 of 25 Research article Neuroscience Kriegeskorte N, Kievit RA. 2013. Representational geometry ...
spectral-signature-and-behavioral-consequence-of-spontaneous-shifts-of-pupil-linked-arousal-in-human.pdf
... that no competing interests exist. Funding: See page 21 Received: 10 March 2021 Accepted: 27 August 2021 Published ... page Research article Neuroscience Podvalny et al. eLife 2021;10:e68265. DOI: https ...
Task-evoked activity quenches neural correlations and variability across cortical areas
... ) the system approaches the fixed point. c) We ran simulations across a range of stimulation amplitudes ... and correlations by investigating the effects of task-state activity on the underlying neu- ral attractor dynamics ...
A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
This study is designed to test how effective a new drug called AZD0486 (BITE for CD19) is for patients relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) who have already tried at least 1-2 other treatments. This study has three parts: Part A will test increasing doses of AZD0486 to find a dose with few side effects; Part B will test up to two doses from Part A to decide the best dose to use in the next phase; and Part C will use the best dose from Part B to see how well it works in more patients. AZD0486 will be given as an IV infusion on certain days of each 28-day cycle, with close monitoring for side effects. Side effects and effectiveness will be checked regularly, and the study will continue until enough data is collected to understand how well AZD0486 works and how safe it is.
A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
A Multicenter Open-Label Study of RMC-6236 inPatients with Advanced Solid Tumors Harboring Specific Mutations in RAS
A Phase 1/2 Multicenter Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with MTAP Loss and RAS Mutation
This Phase 1/2 study will determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805.Overall, the study comprises a dose escalation phase and a dose expansion phase.
A Randomized Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This is a phase 3 study testing and comparing if study medicine amivantamab (monoclonal antibody) in combination with mFOLFOX6 or FOLFIRI (chemotherapy) is more beneficial than another medicine called cetuximab (Monoclonal antibody) in combination with mFOLFOX6 or FOLFIRI for patients whose colorectal cancer has spread from the primary location and that the tumor has KRAS/NRAS and BRAF wild-type genes. Patients will be divided into two groups. One group will receive amivantamab together with mFOLFOX6 or FOLFIRI, and the other group will receive cetuximab and mFOLFOX6 or FOLFIRI. All participants will have special scans taken to see if the study treatment is changing their tumor size and that the cancer is not progressing. The study team will collect blood samples from all patients to see how their bodies are responding to these medicines and whether antibodies to the study medicine are formed. Genetic testing will be done on blood and tumor samples in the hope of further helping patients. All patients will be monitored for side effects and safety throughout the study.